Renovaro Group is driven by a steadfast commitment to revolutionize healthcare.
WHAT WE DO
Renovaro Group is driven by a steadfast commitment to revolutionize healthcare.
Our primary goals encompass pioneering advancements in biotechnology to develop groundbreaking therapies and diagnostic tools.
We aim to address unmet medical needs in diverse areas such as oncology, neurology, infectious diseases, and rare genetic disorders.
ABOUT RENOVAROCUBE
RenovaroCube is working to transform cancer detection through its advanced AI/Machine Learning platform that harnesses the power of multi-omics analysis and differential molecular capabilities. With access to vast amounts of big data, RenovaroCube is at the forefront of leveraging data mining techniques. Our unique library of over 2600 biomarker panels offers the flexibility to create custom panels for the pharmaceutical industry.
We are rapidly working to expand our platform for as many cancers as we possibly can. Utilizing differential molecular diagnosis and multi-omic analysis, our platform aims to enhance accuracy in the detection of multiple cancers, with a view to identifying them before traditional methods may find them. Our state-of-the-art AI/ML platform supports precision oncology, offering significant capabilities in minimal residual disease and recurrence monitoring. Thus, supporting patients in readmission allows routine checks, via blood draw, to be carried out, assessed, and then acted upon.
.
10+
Years of experience
2600+
ProprietaryBiomarker Panels
13
Tumors Validated In-Silico
Why work with us?
Differential Molecular Diagnostics
Based on biomarkers, genetics, tumor sequencing, & liquid biopsies.
Fast Discovery Process
After lab results and raw data have been supplied, results can be produced swiftly.
Precision Diagnostics
With a high accuracy target of > 95% based on proprietary algorithm.
Explainable AI
Every prediction is traceable and interpretable to the exact biomarkers, panels and genes.
High Reliability
High specificity target (>99%) and sensitivity (>70%).
Reduce Costs
For drug discovery and validation, the process is accelerated saving (expensive) R&D costs.
ABOUT RENOVAROBIO
We are a biotechnology company focused on developing advanced allogeneic cell and gene therapies to enhance immune responses, aiming for long-term cancer remission and potential cures for serious diseases such as HIV and HBV. Our strategy relies on using allogeneic cells to boost immune responses.
We develop an off the shelf cell and gene therapies derived from donors to promote stronger immune system responses to induce long-term or life-long cancer remission in some of the deadliest cancers.
Renovaro has grown from a single HIV treatment candidate to include two additional HIV candidates, an HBV pipeline, and expanded into cancer immunotherapies, specifically targeting challenging solid tumors like pancreatic cancer, which is now a primary focus.
Our Team
COMMITTED TO RADICALLY ACCELERATE PRECISION MEDICINE
Maurice van Tilburg – Glimne
Chairman
David Weinstein
Director & Chief Executive Officer (CEO)
Douglas W. Calder
Director
Mark Collins, Phd
Director
James A. McNulty
Director
Simon Tarsh
Interim Chief Financial Officer (CFO)
